Merck & Company (MRK) 55.85 $MRK
After Yesterday's Decline of 1.06%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 28, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $54.10 to a high of $56.60. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $55.92 on volume of 23.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 55.85 (-0.60)
Is Twitter's Growth Story Over or Is It Just Getting Started?
at The Street - Tue Oct 28, 3:12PM CDT
CNBC's 'Fast Money' trading panel takes a look at whether investors should buy shares of Twitter on the recent pullback.
TSLA: 242.77 (+21.10), KSS: 54.66 (-3.89), HTZ: 22.43 (+1.05), HES: 81.95 (+1.64), FB: 80.77 (+0.49), PFE: 29.09 (+0.06), M: 57.27 (-1.22), BWLD: 151.68 (+17.86), UAL: 52.36 (+0.63), MSG: 72.99 (+7.21), COH: 34.00 (-2.15), MRK: 55.85 (-0.60), EOG: 91.50 (+3.07), AAL: 40.24 (+0.33), GM: 31.17 (+1.09), GOOGL: 558.94 (+9.06), TWTR: 43.78 (-4.78)
Merck (MRK) Stock Continues to Fall After Third-Quarter Earnings Report
at The Street - Tue Oct 28, 2:26PM CDT
Shares of Merck (MRK) continue to decline in afternoon trading Tuesday after the pharmaceutical company announced a year-over-year decline in net income its third-quarter earnings results on Monday.
MRK: 55.85 (-0.60)
Global Women's Health Market 2014-2018: Key Vendors are Actavis, Bayer, Eli Lilly and Co, Merck & Co and Pfizer
PR Newswire - Tue Oct 28, 1:52PM CDT
Research and Markets has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering.
MRK: 55.85 (-0.60)
French Drugmaker Sanofi Warns Of Tougher Competition
at Investor's Business Daily - Tue Oct 28, 1:42PM CDT
Stock in Sanofi fell Tuesday after the French drugmaker warned that sales of its diabetes products face a more challenging environment due to mounting competition in the U.S. The warning comes amid tension at the top of the company. On Monday, Sanofi...
NVO: 43.50 (-2.30), MRK: 55.85 (-0.60), LLY: 64.83 (-1.37), SNY: 48.07 (-4.75)
Video: Facebook, Gilead Post Earnings After The Close
at Investor's Business Daily - Tue Oct 28, 1:00PM CDT
Two top stocks on Leaderboard's Leaders List report quarterly earnings after the close on Tuesday: Facebook and Gilead Sciences. Here's a breakdown of what analysts expect. The social network's earnings are seen jumping 60% to 40 cents a share minus...
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), FB: 80.77 (+0.49), MRK: 55.85 (-0.60)
Most active New York Stock Exchange-traded stocks
AP - Tue Oct 28, 12:26PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
GE: 25.88 (+0.36), F: 14.16 (+0.34), CLV: 10.57 (+1.49), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), HAL: 53.26 (+0.87), GM: 31.17 (+1.09), CLF: 11.29 (+2.05), BAC: 16.80 (+0.21), TWTR: 43.78 (-4.78), DOW: 47.98 (+1.49), RAD: 5.06 (+0.26)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 32.61 (+0.31), VRX: 131.07 (+0.51), NBR: 17.62 (+0.14), HAL: 53.26 (+0.87), XOM: 95.10 (+1.39), BRCD: 10.58 (+0.26), SLB: 96.51 (+2.99), AGN: 182.60 (+0.27), CHK: 21.60 (+0.81), MRK: 55.85 (-0.60), EOG: 91.50 (+3.07), DD: 67.95 (+0.07), PX: 125.70 (+0.19), CVX: 117.13 (+2.11), VZ: 49.96 (+0.54), DOW: 47.98 (+1.49), ECL: 110.61 (-0.03)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.38 (+0.07), MRK: 55.85 (-0.60), PFE: 29.09 (+0.06), SRPT: 15.12 (-0.79), NLNK: 34.90 (-3.02), TKMR: 18.33 (+0.06), GSK: 45.10 (-0.27), NVS: 92.35 (+2.14)
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 318.03 (-1.95), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), NVS: 92.35 (+2.14)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 182.60 (+0.27), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), DEPO: 15.44 (+0.36), GSK: 45.10 (-0.27)
Global Schizoaffective Disorder Clinical Trials Report H2, 2014
M2 - Tue Oct 28, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3w59x2/schizoaffective) has announced the addition of the "Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" report to their offering. Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" provides data on the Schizoaffective Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizoaffective Disorder. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizoaffective Disorder. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Johnson & Johnson - Pfizer Inc. - Eli Lilly and Company - AstraZeneca PLC - Bristol-Myers Squibb Company - Sumitomo Dainippon Pharma Co., Ltd. - Otsuka Holdings Co., Ltd. - AbbVie Inc. - North Shore-Long Island Jewish Health System, Inc. - Merck & Co., Inc. Top Institutes / Government - U.S. Department of Veterans Affairs - University of Maryland - University of Pittsburgh - Yale University - Centre for Addiction and Mental Health - National Institute of Mental Health - Vanderbilt University - Dartmouth-Hitchcock Medical Center - Massachusetts General Hospital - North Suffolk Mental Health Association For more information visit http://www.researchandmarkets.com/research/3w...oaffective
JNJ: 104.79 (+0.72), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), AZN: 71.43 (+0.67), LLY: 64.83 (-1.37), ABBV: 60.93 (+0.44), BMY: 54.20 (+0.67)
Merck sales fall, miss views
at Investor's Business Daily - Mon Oct 27, 5:55PM CDT
The pharmaceutical giant's Q3 EPS dipped 2.2% to 90 cents but beat views by 2 cents. Revenue fell 4% to $10.56 bil, under views. Sales from its animal-health division rose 11%, but overall pharmaceutical revenue fell 4% after it lost exclusivity on...
MRK: 55.85 (-0.60)
Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales
Sean Williams, The Motley Fool - Motley Fool - Mon Oct 27, 4:16PM CDT
Big pharma giant Merck hasn't been shy about the fact that it's in the midst of a multi-year turnaround strategy focused on generating organic and acquired growth, but shareholders sometimes need a reminder that there could be bumps along the...
GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Stock Market Today: U.S. Stocks Continue to Party as Oil Nears $70s
at The Street - Mon Oct 27, 3:25PM CDT
Brazil’s runoff presidential election, a Goldman Sachs downgrade across the oil patch and bank stress tests in the European Union did little to impact U.S. stock markets.
AGN: 182.60 (+0.27), PBR: 11.68 (+0.52), VRX: 131.07 (+0.51), RIG: 29.89 (+1.37), NBR: 17.62 (+0.14), MRK: 55.85 (-0.60), XOM: 95.10 (+1.39), CVX: 117.13 (+2.11)
Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble
at Investor's Business Daily - Mon Oct 27, 2:38PM CDT
Shares of Gilead Sciences (GILD) hit a new high near 113 in the stock market today as the biotech prepared to deliver its Q3 report after the close Tuesday, while an analyst noted that a couple of its potential competitors seemed to be faltering....
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Stock Market Today: Oil Drives Stocks Lower as Goldman Sees Crude at $74 a Barrel
at The Street - Mon Oct 27, 2:03PM CDT
U.S. stocks decline with the energy sector leading markets lower after Goldman Sachs says it expects the price of WTI to trade at $74 a barrel in 2015.
AGN: 182.60 (+0.27), PBR: 11.68 (+0.52), VRX: 131.07 (+0.51), MRK: 55.85 (-0.60), XOM: 95.10 (+1.39), CVX: 117.13 (+2.11)
Can U.S. Stocks Go Higher if Oil Prices Keep Going Lower?
at The Street - Mon Oct 27, 1:56PM CDT
The "Fast Money" trading panel discussed the impact of falling oil prices on the stock market.
FDX: 168.20 (+2.98), BX: 30.55 (+0.16), NKE: 92.45 (+0.81), XBI: 171.51 (+4.30), GRMN: 57.20 (+0.59), PCL: 40.16 (-1.19), UPS: 102.90 (+0.65), TCBI: 59.71 (+2.19), UA: 64.30 (-0.41), SPY: 198.41 (+2.25), QQQ: 100.18 (+1.49), MPC: 89.12 (+2.70), SRPT: 15.12 (-0.79), MRK: 55.85 (-0.60), DIA: 169.66 (+1.78), STI: 38.43 (+0.58), CFG: 23.28 (+0.43), TEVA: 54.80 (+0.80), FL: 55.46 (+0.41), AAPL: 106.74 (+1.63), XLE: 85.71 (+1.91)
Dow Jones (DJIA) Today: Merck (MRK) Lower
at The Street - Mon Oct 27, 12:00PM CDT
Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a $1.54 decline (-2.7%) bringing the stock to $56.07.
MRK: 55.85 (-0.60)
After Yesterday's Decline of 1.06%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 28, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $54.10 to a high of $56.60. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $55.92 on volume of 23.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 55.85 (-0.60)
Is Twitter's Growth Story Over or Is It Just Getting Started?
at The Street - Tue Oct 28, 3:12PM CDT
CNBC's 'Fast Money' trading panel takes a look at whether investors should buy shares of Twitter on the recent pullback.
TSLA: 242.77 (+21.10), KSS: 54.66 (-3.89), HTZ: 22.43 (+1.05), HES: 81.95 (+1.64), FB: 80.77 (+0.49), PFE: 29.09 (+0.06), M: 57.27 (-1.22), BWLD: 151.68 (+17.86), UAL: 52.36 (+0.63), MSG: 72.99 (+7.21), COH: 34.00 (-2.15), MRK: 55.85 (-0.60), EOG: 91.50 (+3.07), AAL: 40.24 (+0.33), GM: 31.17 (+1.09), GOOGL: 558.94 (+9.06), TWTR: 43.78 (-4.78)
Merck (MRK) Stock Continues to Fall After Third-Quarter Earnings Report
at The Street - Tue Oct 28, 2:26PM CDT
Shares of Merck (MRK) continue to decline in afternoon trading Tuesday after the pharmaceutical company announced a year-over-year decline in net income its third-quarter earnings results on Monday.
MRK: 55.85 (-0.60)
Global Women's Health Market 2014-2018: Key Vendors are Actavis, Bayer, Eli Lilly and Co, Merck & Co and Pfizer
PR Newswire - Tue Oct 28, 1:52PM CDT
Research and Markets has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering.
MRK: 55.85 (-0.60)
French Drugmaker Sanofi Warns Of Tougher Competition
at Investor's Business Daily - Tue Oct 28, 1:42PM CDT
Stock in Sanofi fell Tuesday after the French drugmaker warned that sales of its diabetes products face a more challenging environment due to mounting competition in the U.S. The warning comes amid tension at the top of the company. On Monday, Sanofi...
NVO: 43.50 (-2.30), MRK: 55.85 (-0.60), LLY: 64.83 (-1.37), SNY: 48.07 (-4.75)
Video: Facebook, Gilead Post Earnings After The Close
at Investor's Business Daily - Tue Oct 28, 1:00PM CDT
Two top stocks on Leaderboard's Leaders List report quarterly earnings after the close on Tuesday: Facebook and Gilead Sciences. Here's a breakdown of what analysts expect. The social network's earnings are seen jumping 60% to 40 cents a share minus...
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), FB: 80.77 (+0.49), MRK: 55.85 (-0.60)
Most active New York Stock Exchange-traded stocks
AP - Tue Oct 28, 12:26PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
GE: 25.88 (+0.36), F: 14.16 (+0.34), CLV: 10.57 (+1.49), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), HAL: 53.26 (+0.87), GM: 31.17 (+1.09), CLF: 11.29 (+2.05), BAC: 16.80 (+0.21), TWTR: 43.78 (-4.78), DOW: 47.98 (+1.49), RAD: 5.06 (+0.26)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 32.61 (+0.31), VRX: 131.07 (+0.51), NBR: 17.62 (+0.14), HAL: 53.26 (+0.87), XOM: 95.10 (+1.39), BRCD: 10.58 (+0.26), SLB: 96.51 (+2.99), AGN: 182.60 (+0.27), CHK: 21.60 (+0.81), MRK: 55.85 (-0.60), EOG: 91.50 (+3.07), DD: 67.95 (+0.07), PX: 125.70 (+0.19), CVX: 117.13 (+2.11), VZ: 49.96 (+0.54), DOW: 47.98 (+1.49), ECL: 110.61 (-0.03)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.38 (+0.07), MRK: 55.85 (-0.60), PFE: 29.09 (+0.06), SRPT: 15.12 (-0.79), NLNK: 34.90 (-3.02), TKMR: 18.33 (+0.06), GSK: 45.10 (-0.27), NVS: 92.35 (+2.14)
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 318.03 (-1.95), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), NVS: 92.35 (+2.14)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 182.60 (+0.27), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), DEPO: 15.44 (+0.36), GSK: 45.10 (-0.27)
Global Schizoaffective Disorder Clinical Trials Report H2, 2014
M2 - Tue Oct 28, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3w59x2/schizoaffective) has announced the addition of the "Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" report to their offering. Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" provides data on the Schizoaffective Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizoaffective Disorder. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizoaffective Disorder. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Johnson & Johnson - Pfizer Inc. - Eli Lilly and Company - AstraZeneca PLC - Bristol-Myers Squibb Company - Sumitomo Dainippon Pharma Co., Ltd. - Otsuka Holdings Co., Ltd. - AbbVie Inc. - North Shore-Long Island Jewish Health System, Inc. - Merck & Co., Inc. Top Institutes / Government - U.S. Department of Veterans Affairs - University of Maryland - University of Pittsburgh - Yale University - Centre for Addiction and Mental Health - National Institute of Mental Health - Vanderbilt University - Dartmouth-Hitchcock Medical Center - Massachusetts General Hospital - North Suffolk Mental Health Association For more information visit http://www.researchandmarkets.com/research/3w...oaffective
JNJ: 104.79 (+0.72), PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), AZN: 71.43 (+0.67), LLY: 64.83 (-1.37), ABBV: 60.93 (+0.44), BMY: 54.20 (+0.67)
Merck sales fall, miss views
at Investor's Business Daily - Mon Oct 27, 5:55PM CDT
The pharmaceutical giant's Q3 EPS dipped 2.2% to 90 cents but beat views by 2 cents. Revenue fell 4% to $10.56 bil, under views. Sales from its animal-health division rose 11%, but overall pharmaceutical revenue fell 4% after it lost exclusivity on...
MRK: 55.85 (-0.60)
Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales
Sean Williams, The Motley Fool - Motley Fool - Mon Oct 27, 4:16PM CDT
Big pharma giant Merck hasn't been shy about the fact that it's in the midst of a multi-year turnaround strategy focused on generating organic and acquired growth, but shareholders sometimes need a reminder that there could be bumps along the...
GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Stock Market Today: U.S. Stocks Continue to Party as Oil Nears $70s
at The Street - Mon Oct 27, 3:25PM CDT
Brazil’s runoff presidential election, a Goldman Sachs downgrade across the oil patch and bank stress tests in the European Union did little to impact U.S. stock markets.
AGN: 182.60 (+0.27), PBR: 11.68 (+0.52), VRX: 131.07 (+0.51), RIG: 29.89 (+1.37), NBR: 17.62 (+0.14), MRK: 55.85 (-0.60), XOM: 95.10 (+1.39), CVX: 117.13 (+2.11)
Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble
at Investor's Business Daily - Mon Oct 27, 2:38PM CDT
Shares of Gilead Sciences (GILD) hit a new high near 113 in the stock market today as the biotech prepared to deliver its Q3 report after the close Tuesday, while an analyst noted that a couple of its potential competitors seemed to be faltering....
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Stock Market Today: Oil Drives Stocks Lower as Goldman Sees Crude at $74 a Barrel
at The Street - Mon Oct 27, 2:03PM CDT
U.S. stocks decline with the energy sector leading markets lower after Goldman Sachs says it expects the price of WTI to trade at $74 a barrel in 2015.
AGN: 182.60 (+0.27), PBR: 11.68 (+0.52), VRX: 131.07 (+0.51), MRK: 55.85 (-0.60), XOM: 95.10 (+1.39), CVX: 117.13 (+2.11)
Can U.S. Stocks Go Higher if Oil Prices Keep Going Lower?
at The Street - Mon Oct 27, 1:56PM CDT
The "Fast Money" trading panel discussed the impact of falling oil prices on the stock market.
FDX: 168.20 (+2.98), BX: 30.55 (+0.16), NKE: 92.45 (+0.81), XBI: 171.51 (+4.30), GRMN: 57.20 (+0.59), PCL: 40.16 (-1.19), UPS: 102.90 (+0.65), TCBI: 59.71 (+2.19), UA: 64.30 (-0.41), SPY: 198.41 (+2.25), QQQ: 100.18 (+1.49), MPC: 89.12 (+2.70), SRPT: 15.12 (-0.79), MRK: 55.85 (-0.60), DIA: 169.66 (+1.78), STI: 38.43 (+0.58), CFG: 23.28 (+0.43), TEVA: 54.80 (+0.80), FL: 55.46 (+0.41), AAPL: 106.74 (+1.63), XLE: 85.71 (+1.91)
Dow Jones (DJIA) Today: Merck (MRK) Lower
at The Street - Mon Oct 27, 12:00PM CDT
Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a $1.54 decline (-2.7%) bringing the stock to $56.07.
MRK: 55.85 (-0.60)
